Literature DB >> 12742662

The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood.

Luba Lopatinskaya1, Anette H H van Boxel-Dezaire, Frederik Barkhof, Chris H Polman, Cornelis J Lucas, Lex Nagelkerken.   

Abstract

In this longitudinal study, we examined the expression of Fas, FasL, CCR3, CCR5 and CXCR3 mRNA in peripheral blood mononuclear cells (PBMCs) of secondary progressive (SP) and relapsing-remitting (RR) multiple sclerosis (MS) patients. In RR patients, FasL, CCR3 and CCR5 mRNA levels were increased prior to the exacerbations, but these decreased during clinical activity, while mRNA levels of Fas increased. SP patients have increased the levels of Fas and FasL mRNA; the latter was particularly increased during lesional activity. Our data support the hypothesis that changes in Fas and FasL mRNA related to clinical activity are due to the migration of inflammatory cells to the central nervous system (CNS).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742662     DOI: 10.1016/s0165-5728(03)00089-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  3 in total

1.  RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.

Authors:  Adam M Kruszewski; Gautam Rao; Alexandru Tatomir; Daniel Hewes; Cosmin A Tegla; Cornelia D Cudrici; Vingh Nguyen; Walter Royal; Christopher T Bever; Violeta Rus; Horea Rus
Journal:  Exp Mol Pathol       Date:  2015-09-25       Impact factor: 3.362

Review 2.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

3.  MK2 and Fas receptor contribute to the severity of CNS demyelination.

Authors:  Silvia M Tietz; Regina Hofmann; Tobias Thomas; Björn Tackenberg; Matthias Gaestel; Martin Berghoff
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.